Exploring the use of novel drug delivery systems for antiretroviral drugs

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 70, Issue 3, 2008, Pages 697-710

  Ojewole, Elizabeth ^a   Mackraj, Irene ^a   Naidoo, Panjasaram ^a   Govender, Thirumala ^a  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

Antiretroviral drugs; HIV AIDS; Novel drug delivery systems; Sustained release; Targeting

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; DELAVIRDINE; DENDRIMER; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; EMULSIFYING AGENT; ENFUVIRTIDE; ETHYL CELLULOSE; ETRAVIRINE; EUDRAGIT; LAMIVUDINE; LIPOSOME; LOVIRIDE; MARAVIROC; NANOPARTICLE; NELFINAVIR; NEVIRAPINE; PHEROID; RALTEGRAVIR; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CERAMIC PROSTHESIS; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG SOLUBILITY; DRUG STABILITY; DRUG TARGETING; EMULSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MICELLE; MICROEMULSION; REVIEW; SUSTAINED DRUG RELEASE; SUSTAINED RELEASE PREPARATION;

ANIMALS; ANTI-RETROVIRAL AGENTS; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION ROUTES; DRUG CARRIERS; DRUG COMPOUNDING; DRUG STABILITY; HIV INFECTIONS; HUMANS; SOLUBILITY;

EID: 54949136864     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2008.06.020     Document Type: Review

References (130)

1. Fauci A.S., and Lane H.C. The acquired immunodeficiency syndrome (AIDS). In: Wilson J.D., Braunwald E., Isselbacher K.J., Peterdorf R.G., Martin J.B., Fauci A.S., and Root R.K. (Eds). Harrison's Principles of Internal Medicine. 12th ed. (1991), McGraw-Hill, New York 1402-1410
2. Naidoo P. Barriers to HIV care and treatment by doctors: a review of the literature. SA Fam. Pract. 48 (2006) 53
3. UNAIDS, AIDS Epidemic Update, 2007. Available from: (accessed 29.11.07).
4. Girard M.P., Osmanov S.K., and Kieny M.P. A review of vaccine research and development: the human immunodeficiency virus (HIV). Vaccine 24 (2006) 4062-4081
5. Chinen J., and Shearer W.T. Secondary immunodeficiencies, including HIV infection. J. Allergy Clin. Immunol. 121 (2008) S388-S392 quiz S417
6. Lucas S. Update on the pathology of AIDS. Intensive Crit. Care Nurs. 17 (2001) 155-166
7. Littman D.R. Chemokine receptors: keys to AIDS pathogenesis?. Cell 93 (1998) 677-680
8. McArthur J.C., Brew B.J., and Nath A. Neurological complications of HIV infection. Lancet Neurol. 4 (2005) 543-555
9. Arendt C.W., and Littman D.R. HIV: master of the host cell. Genome Biol. 2 (2001) Reviews 1030
10. Learmont J.C., et al. Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort. N. Engl. J. Med. 340 (1999) 1715-1722
11. Stoddart C., and Reyes R. Models of HIV-1 disease: a review of current status. Drug Discov. Today Dis. Models 3 (2006) 113-119
12. Vyas T.K., Shah L., and Amiji M.M. Nanoparticulate drug carriers for delivery of HIV/AIDS therapy to viral reservoir sites. Expert Opin. Drug Deliv. 3 (2006) 613-628
13. Flexner C. HIV drug development: the next 25 years. Nat. Rev. Drug Discov. 6 (2007) 959-966
14. Rathbun R.C., Lockhart S.M., and Stephens J.R. Current HIV treatment guidelines - an overview. Curr. Pharm. Des. 12 (2006) 1045-1063
15. Sande M.A., Moellering R.C., and Gilbert D.N. The Sanford Guide to HIV/AIDS Therapy (2003), Antimicrobial Therapy, Inc., US
16. R.A. Elion, D. Mallory, Nucleoside and Nucleotide Reverse Transcriptase Inhibitors in the Treatment of HIV: Focus on efficacy. Available from: (accessed 24.10.07).
17. Antiretroviral Treatment Basics, HIV Treatment Guidelines: Therapeutic Drug Monitoring Pacific AIDS Education and Training Centre. Available from: (accessed 24.10.07).
18. HIV/AIDS Drug Information, US Department of Health and Human Services (DHHS). Available from: (accessed 24.10.07).
19. RxList The Internet Drug Index, RxList Inc. Available from: (accessed 27.03.08).
20. Lanao J.M., Briones E., and Colino C.I. Recent advances in delivery systems for anti-HIV1 therapy. J. Drug Target. 15 (2007) 21-36
21. L. Highleyman, HIV Drugs and the HIV Lifecycle 2003. Available from: (accessed 24.10.07).
22. D. Pieribone, The HIV Life Cycle 2002/2003. Available from: (accessed 24.10.07).
23. Li J., Tang S., Hewlett I., and Yang M. HIV-1 capsid protein and cyclophilin as new targets for anti-AIDS therapeutic agents. Infect. Disord. Drug Targets 7 (2007) 238-244
24. Li X.L., and Chan W.K. Transport, metabolism and elimination mechanisms of anti-HIV agents. Adv. Drug Deliv. Rev. 39 (1999) 81-103
25. Vyas S.P., Subhedar R., and Jain S. Development and characterization of emulsomes for sustained and targeted delivery of an antiviral agent to liver. J. Pharm. Pharmacol. 58 (2006) 321-326
26. Amiji M.M., Vyas T.K., and Shah L.K. Role of nanotechnology in HIV/AIDS treatment: potential to overcome the viral reservoir challenge. Discov. Med. 6 (2006) 157-162
27. Xiang J., Fang X., and Li X. Transbuccal delivery of 2′,3′-dideoxycytidine: in vitro permeation study and histological investigation. Int. J. Pharm. 231 (2002) 57-66
28. Mirchandani H., and Chien Y.W. Drug delivery approaches for anti-HIV drugs. Int. J. Pharm. 95 (1993) 1-21
29. Gates K.A., et al. A new bioerodible polymer insert for the controlled release of metronidazole. Pharm. Res. 11 (1994) 1605-1609
30. Banaker U.V. Drug delivery systems of the nineties: innovations in controlled release. Am. Pharm. 2 (1987) 39-48
31. Kamath K.R., and Park K. Mucosal adhesive preparations. In: Swabrick J., and Boylan J.C. (Eds). Encyclopedia of Pharmaceutical Technology (1994), Marcel Dekker, New York 133-163
32. Betageri G.V., Deshmukh D.V., and Gupta R.B. Oral sustained-release bioadhesive tablet formulation of didanosine. Drug Dev. Ind. Pharm. 27 (2001) 129-136
33. Munasur A.P., Pillay V., Chetty D.J., and Govender T. Statistical optimisation of the mucoadhesivity and characterization of multipolymeric propranolol matrices for buccal therapy. Int. J. Pharm. 323 (2006) 43-51
34. Govender S., Pillay V., Chetty D.J., Essack S.Y., Dangor C.M., and Govender T. Optimisation and characterisation of bioadhesive controlled release tetracycline microspheres. Int. J. Pharm. 306 (2005) 24-40
35. Perugini P., Genta I., Conti B., Modena T., and Pavanetto F. Periodontal delivery of ipriflavone: new chitosan/PLGA film delivery system for a lipophilic drug. Int. J. Pharm. 252 (2003) 1-9
36. Sanchez-Lafuente C., Furlanetto S., Fernandez-Arevalo M., Alvarez-Fuentes J., Rabasco A.M., Faucci M.T., Pinzauti S., and Mura P. Didanosine extended-release matrix tablets: optimization of formulation variables using statistical experimental design. Int. J. Pharm. 237 (2002) 107-118
37. Sanchez-Lafuente C., Teresa Faucci M., Fernandez-Arevalo M., Alvarez-Fuentes J., Rabasco A.M., and Mura P. Development of sustained release matrix tablets of didanosine containing methacrylic and ethylcellulose polymers. Int. J. Pharm. 234 (2002) 213-221
38. Anderson B.D., Wyangst M.B., Xiang T., Waugh W.A., and Stella V. Preformulation solubility and kinetic studies of 2′,3′-dideoxypurine nucleotides: potential anti-Aids agents. Int. J. Pharm. 45 (1988) 27-37
39. Deshmukh D., Ravis W.R., and Betageri G.V. Delivery of didanosine from enteric-coated, sustained-release bioadhesive formulation. Drug Deliv. 10 (2003) 47-50
40. 3H-thymidine by means of ceramic capsules in rats. Biomed. Sci. Instrum. 25 (1989) 169-177
41. Benghuzzi H.A., Barbaro R.M., and Bajpai P.K. In vitro release of azidothymidine (AZT) by ceramic drug delivery systems. Biomed. Sci. Instrum. 26 (1990) 151-156
42. Nagy E.A., and Bajpai P.K. Development of a ceramic matrix system for continuous delivery of azidothymidine. Biomed. Sci. Instrum. 30 (1994) 181-186
43. Cannon M.R., and Bajpai P.K. Continuous delivery of azidothymidine by hydroxyapatite or tricalcium phosphate ceramics. Biomed. Sci. Instrum. 31 (1995) 159-164
44. Reed D., Billotte W.G., Rush B.J., Odorzynski A., Kreinbrink K., and Bajpai P.K. Hydroxyapatite-oil composites for delivering AZT in simulated body fluid. Biomed. Sci. Instrum. 34 (1997) 59-64
45. Benghuzzi H. Long-term sustained delivery of 3′-azido-2′,3′-dideoxythymidine in vivo by means of HA and TCP delivery devices. Biomed. Sci. Instrum. 36 (2000) 343-348
46. Sharma A., and Sharma U.S. Liposomes in drug delivery: progress and limitations. Int. J. Pharm. 154 (1997) 123-140
47. Desormeaux A., and Bergeron M.G. Liposomes as drug delivery system: a strategic approach for the treatment of HIV infection. J. Drug Target. 6 (1998) 1-15
48. Jin S.X., Bi D.Z., Wang J., Wang Y.Z., Hu H.G., and Deng Y.H. Pharmacokinetics and tissue distribution of zidovudine in rats following intravenous administration of zidovudine myristate loaded liposomes. Pharmazie 60 (2005) 840-843
49. Phillips N.C., Skamene E., and Tsoukas C. Liposomal encapsulation of 3′-azido-3′-deoxythymidine (AZT) results in decreased bone marrow toxicity and enhanced activity against murine AIDS-induced immunosuppression. J. Acquir. Immune Defic. Syndr. 4 (1991) 959-966
50. Phillips N.C., and Tsoukas C. Liposomal encapsulation of azidothymidine results in decreased hematopoietic toxicity and enhanced activity against murine acquired immunodeficiency syndrome. Blood 79 (1992) 1137-1143
51. Subheet J., Tiwary A.K., and Jain N.K. Sustained and targeted delivery of an anti-HIV agent using elastic liposomal formulation: mechanism of action. Curr. Drug Deliv. 3 (2006) 157-166
52. Harvie P., Desormeaux A., Gagne N., Tremblay M., Poulin L., Beauchamp D., and Bergeron M.G. Lymphoid tissues targeting of liposome-encapsulated 2′,3′-dideoxyinosine. Aids 9 (1995) 701-707
53. Harvie P., Desormeaux A., Bergeron M.C., Tremblay M., Beauchamp D., Poulin L., and Bergeron M.G. Comparative pharmacokinetics, distributions in tissue, and interactions with blood proteins of conventional and sterically stabilized liposomes containing 2′,3′-dideoxyinosine. Antimicrob. Agents Chemother. 40 (1996) 225-229
54. Makabi-Panzu B., Lessard C., Beauchamp D., Desormeaux A., Poulin L., Tremblay M., and Bergeron M.G. Uptake and binding of liposomal 2′,3′-dideoxycytidine by RAW 264.7 cells: a three-step process. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 8 (1995) 227-235
55. Makabi-Panzu B., Gourde P., Desormeaux A., and Bergeron M.G. Intracellular and serum stability of liposomal 2′,3′-dideoxycytidine. Effect of lipid composition. Cell Mol. Biol. (Noisy-le-grand) 44 (1998) 277-284
56. Rossi L., Brandi G., Schiavano G.F., Chiarantini L., Albano A., and Magnani M. In vitro and in vivo toxicity of 2′,3′-dideoxycytidine in mice. Chem. Biol. Interact. 85 (1992) 255-263
57. Szebeni J., Wahl S.M., Betageri G.V., Wahl L.M., Gartner S., Popovic M., Parker R.J., Black C.D., and Weinstein J.N. Inhibition of HIV-1 in monocyte/macrophage cultures by 2′,3′-dideoxycytidine-5′-triphosphate, free and in liposomes. AIDS Res. Hum. Retroviruses 6 (1990) 691-702
58. Oussoren C., Magnani M., Fraternale A., Casabianca A., Chiarantini L., Ingebrigsten R., Underberg W.J., and Storm G. Liposomes as carriers of the antiretroviral agent dideoxycytidine-5′-triphosphate. Int. J. Pharm. 180 (1999) 261-270
59. Lalanne M., et al. Synthesis and biological evaluation of two glycerolipidic prodrugs of didanosine for direct lymphatic delivery against HIV. Bioorg. Med. Chem. Lett. 17 (2007) 2237-2240
60. Torchilin V.P., Klibanov A.L., Huang L., O'Donnell S., Nossiff N.D., and Khaw B.A. Targeted accumulation of polyethylene glycol-coated immunoliposomes in infarcted rabbit myocardium. FASEB J. 6 (1992) 2716-2719
61. Allen T.M. Long-circulating (sterically stabilized) liposomes for targeted drug delivery. Trends Pharmacol. Sci. 15 (1994) 215-220
62. Betageri G.V., and Burrell L.S. Stability of antibody-bearing liposomes containing dideoxyinosine triphosphate. Int. J. Pharm. 98 (1993) 149-155
63. Gagne J.F., Desormeaux A., Perron S., Tremblay M.J., and Bergeron M.G. Targeted delivery of indinavir to HIV-1 primary reservoirs with immunoliposomes. Biochim. Biophys. Acta 1558 (2002) 198-210
64. Garg M., Asthana A., Agashe H.B., Agrawal G.P., and Jain N.K. Stavudine-loaded mannosylated liposomes: in-vitro anti-HIV-I activity, tissue distribution and pharmacokinetics. J. Pharm. Pharmacol. 58 (2006) 605-616
65. Garg M., Dutta T., and Jain N.K. Reduced hepatic toxicity, enhanced cellular uptake and altered pharmacokinetics of stavudine loaded galactosylated liposomes. Eur. J. Pharm. Biopharm. 67 (2007) 76-85
66. Wu H.B., Deng Y.H., Wang S.N., Zhou X.Y., Wang N., and Shi L. The distribution of azidothymidine palmitate galactosylated liposomes in mice. Yao Xue Xue Bao 42 (2007) 538-544
67. Slepushkin V.A., Salem I.I., Andreev S.M., Dazin P., and Duzgunes N. Targeting of liposomes to HIV-1-infected cells by peptides derived from the CD4 receptor. Biochem. Biophys. Res. Commun. 227 (1996) 827-833
68. Kompella U.B., Aukunuru J.V., and Betageri G.V. Effect of neutral liposomes on corneal and conjunctival transport of didanosine. Drug Deliv. 6 (1999) 9-14
69. Betageri G.V. Liposomal encapsulation and stability of dideoxyinosine triphosphate. Drug Dev. Ind. Pharm. 19 (1993) 531-539
70. Panyam J., and Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev. 55 (2003) 329-347
71. Brannon-Peppas L., and Blanchette J.O. Nanoparticle and targeted systems for cancer therapy. Adv. Drug Deliv. Rev. 56 (2004) 1649-1659
72. De Jaeghere F., Allemann E., Kubel F., Galli B., Cozens R., Doelker E., and Gurny R. Oral bioavailability of a poorly water soluble HIV-1 protease inhibitor incorporated into pH-sensitive particles: effect of the particle size and nutritional state. J. Control. Release 68 (2000) 291-298
73. Weiss R.A. How does HIV cause AIDS. Science 260 (1993) 1273-1279
74. Schafer V., von Briesen H., Andreesen R., Steffan A.M., Royer C., Troster S., Kreuter J., and Rubsamen-Waigmann H. Phagocytosis of nanoparticles by human immunodeficiency virus (HIV)-infected macrophages: a possibility for antiviral drug targeting. Pharm. Res. 9 (1992) 541-546
75. Bender A., Schfer V., Steffan A.M., Royer C., Kreuter J., Rubsamen-Waigmann H., and von Briesen H. Inhibition of HIV in vitro by antiviral drug-targeting using nanoparticles. Res. Virol. 145 (1994) 215-220
76. Bender A.R., von Briesen H., Kreuter J., Duncan I.B., and Rubsamen-Waigmann H. Efficiency of nanoparticles as a carrier system for antiviral agents in human immunodeficiency virus-infected human monocytes/macrophages in vitro. Antimicrob. Agents Chemother. 40 (1996) 1467-1471
77. Löbenberg R., Araujo L., and Kreuter J. Body distribution of azidothymidine bound to nanoparticles after oral administration. Eur. J. Pharm. Biopharm. 44 (1997) 127-132
78. Löbenberg R., Araujo L., von Briesen H., Rodgers E., and Kreuter J. Body distribution of azidothymidine bound to hexyl-cyanoacrylate nanoparticles after i.v. injection to rats. J. Control. Release 50 (1998) 21-30
79. Stolnik S., Illum L., and Davis S.S. Long circulating microparticulate drug carriers. Adv. Drug Deliv. Rev. 16 (1995) 195-214
80. Shah L.K., and Amiji M.M. Intracellular delivery of saquinavir in biodegradable polymeric nanoparticles for HIV/AIDS. Pharm. Res. 23 (2006) 2638-2645
81. R.M. Mainardes, M.P. Gremião, I.L. Brunetti, L.M. da Fonseca, N.M. Khalil, Zidovudine-loaded PLA and PLA-PEG blend nanoparticles: influence of polymer type on phagocytic uptake by polymorphonuclear cells, J. Pharm. Sci. (2008), in press, doi:10.1002/jps.
82. Vauthier C., Dubernet C., Chauvierre C., Brigger I., and Couvreur P. Drug delivery to resistant tumors: the potential of poly(alkyl cyanoacrylate) nanoparticles. J. Control. Release 93 (2003) 151-160
83. Kuo Y.C., and Su F.L. Transport of stavudine, delavirdine, and saquinavir across the blood-brain barrier by polybutylcyanoacrylate, methylmethacrylate-sulfopropylmethacrylate, and solid lipid nanoparticles. Int. J. Pharm. 340 (2007) 143-152
84. Kuo Y.C. Loading efficiency of stavudine on polybutylcyanoacrylate and methylmethacrylate-sulfopropylmethacrylate copolymer nanoparticles. Int. J. Pharm. 290 (2005) 161-172
85. Govender T., Stolnik S., Garnett M.C., Illum L., and Davis S.S. PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug. J. Control. Release 57 (1999) 171-185
86. Kuo Y.C., and Chen H.H. Effect of nanoparticulate polybutylcyanoacrylate and methylmethacrylate-sulfopropylmethacrylate on the permeability of zidovudine and lamivudine across the in vitro blood-brain barrier. Int. J. Pharm. 327 (2006) 160-169
87. Kuo Y.C., and Kuo C.Y. Electromagnetic interference in the permeability of saquinavir across the blood-brain barrier using nanoparticulate carriers. Int. J. Pharm. 351 (2008) 271-281
88. N. Chattopadhyay, J. Zastre, H.L. Wong, X.Y. Wu, R. Bendayan, Solid lipid nanoparticles enhance the delivery of the HIV protease inhibitor, atazanavir, by a human brain endothelial cell line, Pharm. Res. (2008), in press, doi:10.1007/s11095-008-9615-2.
89. Dou H., et al. Development of macrophage-based nanoparticle platform for antiretroviral drug delivery. Blood 108 (2006) 2827-2837
90. Dou H., et al. Laboratory investigations for the morphologic, pharmacokinetic, and anti-retroviral properties of indinavir nanoparticles in human monocyte-derived macrophages. Virology 358 (2007) 148-158
91. Jain S.K., Gupta Y., Jain A., Saxena A.R., Khare P., and Jain A. Mannosylated gelatin nanoparticles bearing an anti-HIV drug didanosine for site-specific delivery. Nanomedicine 4 (2008) 41-48
92. Kaur A., Jain S., and Tiwary A.K. Mannan-coated gelatine nanoparticles for sustained and targeted delivery of didanosine: in vitro and in vivo evaluation. Acta Pharm. 58 (2008) 61-74
93. Dembri A., Montisci M.J., Gantier J.C., Chacun H., and Ponchel G. Targeting of 3′-azido 3′-deoxythymidine (AZT)-loaded poly(isohexylcyanoacrylate) nanospheres to the gastrointestinal mucosa and associated lymphoid tissues. Pharm. Res. 18 (2001) 467-473
94. Heiati H., Tawashi R., Shivers R.R., and Phillips N.C. Solid lipid nanoparticles as drug carriers I. Incorporation and retention of the lipophilic prodrug 3′-azido-3′-deoxythymidine palmitate. Int. J. Pharm. 146 (1997) 123-131
95. Heiati H., Tawashi R., and Phillips N.C. Solid lipid nanoparticles as drug carriers II. Plasma stability and biodistribution of solid lipid nanoparticles containing the lipophilic prodrug 3′-azido-3′-deoxythymidine palmitate in mice. Int. J. Pharm. 174 (1998) 71-80
96. Boudad H., Legrand P., Appel M., Coconnier M.H., and Ponchel G. Formulation and cytotoxicity of combined cyclodextrin poly(alkylcyanoacrylate) nanoparticles on Caco-2 cells monolayers intended for oral administration of saquinavir. STP Pharma Sci. 11 (2001) 369-375
97. Liu M., and Frechet J.M. Designing dendrimers for drug delivery. Pharm. Sci. Technol. Today 2 (1999) 393-401
98. Tomalia D.A. Birth of a new macromolecular architecture: dendrimers as quantized building blocks for nanoscale synthetic organic chemistry. Aldrichim. Acta 37 (2004) 39-57
99. Dutta T., Agashe H.B., Garg M., Balasubramanium P., Kabra M., and Jain N.K. Poly (propyleneimine) dendrimer based nanocontainers for targeting of efavirenz to human monocytes/macrophages in vitro. J. Drug Target. 15 (2007) 89-98
100. Griffin B.T., and O'Driscoll C.M. A comparison of intestinal lymphatic transport and systemic bioavailability of saquinavir from three lipid-based formulations in the anaesthetised rat model. J. Pharm. Pharmacol. 58 (2006) 917-925
101. Van Eerdenbrugh B., Froyen L., Martens J.A., Blaton N., Augustijns P., Brewster M., and Van den Mooter G. Characterization of physico-chemical properties and pharmaceutical performance of sucrose co-freeze-dried solid nanoparticulate powders of the anti-HIV agent loviride prepared by media milling. Int. J. Pharm. 338 (2007) 198-206
102. Kinman L., et al. Lipid-drug association enhanced HIV-1 protease inhibitor indinavir localization in lymphoid tissues and viral load reduction: a proof of concept study in HIV-2287-infected macaques. J. Acquir. Immune Defic. Syndr. 34 (2003) 387-397
103. Jasti B.R., Williams A., and Ghosh T.K. Transdermal and topical drug delivery systems. In: Ghosh T.K., and Jasti B.R. (Eds). Theory and Practice of Contemporary Pharmaceutics (2005), CRC Press LLC, Boca Raton, FL 423-453
104. Ranade V.V. Transdermal drug delivery. In: Ranade V.V., and Hollinger M.A. (Eds). Drug Delivery Systems (2004), CRC Press, Lewis Publishers, Boca Raton, FL 207-248
105. Narishetty S.T., and Panchagnula R. Transdermal delivery of zidovudine: effect of terpenes and their mechanism of action. J. Control. Release 95 (2004) 367-379
106. Kararli T.T., Kirchhoff C.F., and Penzotti S.C. Enhancement of transdermal transport of azidothymidine (AZT) with novel terpene and terpene-like enhancers: in vivo-in vitro correlations. J. Control. Release 34 (1995) 43-51
107. Oh S.Y., Jeong S.Y., Park T.G., and Lee J.H. Enhanced transdermal delivery of AZT (zidovudine) using iontophoresis and penetration enhancer. J. Control. Release 51 (1998) 161-168
108. Jeong S.Y., Lee J.H., Yuk S.H., and Lee H.B. Transdermal delivery system of anti-AIDS virus agent using a biopolymer. Polymer-Korea 20 (1996) 347-354
109. Gopinath D., Ravi D., Rao B.R., Apte S.S., Renuka D., and Rambhau D. Ascorbyl palmitate vesicles (Aspasomes): formation, characterization and applications. Int. J. Pharm. 271 (2004) 95-113
110. Saunders J., Davis H., Coetzee L., Botha S., Kruger A., and Grobler A. A novel skin penetration enhancer: evaluation by membrane diffusion and confocal microscopy. J. Pharm. Pharm. Sci. 2 (1999) 99-107
111. A.F. Grobler, Emzaloid Technology, North West University, Potchefstroom, 20 (confidential: concept document), 2004, pp. 20.
112. Touitou E., Junginger H.E., Weiner N.D., Nagai T., and Mezei M. Liposomes as carriers for topical and transdermal delivery. J. Pharm. Sci. 83 (1994) 1189-1203
113. Gerber M., Breytenbach J.C., and du Plessis J. Transdermal penetration of zalcitabine, lamivudine and synthesised N-acyl lamivudine esters. Int. J. Pharm. 351 (2008) 186-193
114. Rossi S., Sandri G., and Caramella C.M. Buccal drug delivery: a challenge already won?. Drug Discov. Today Technol. 2 (2005) 59-65
115. Squire C.A., and Hall B.K. The permeability of skin and oral mucosa to water and horseradish peroxidase as related to the thickness of the permeability barrier. J. Invest. Dermatol. 84 (1985) 176-179
116. Rathbone M., Drummond B., and Tucker I. Oral cavity as a site for systemic drug delivery. Adv. Drug Del. Rev. 13 (1994) 1-22
117. Shojaei A.H., Berner B., and Li X.L. Transbuccal delivery of acyclovir: I. In vitro determination of routes of buccal transport. Pharm. Res. 15 (1998) 1182-1188
118. Kawaguchi T., Hasegawa T., Juni K., and Seki T. Rectal absorption of zidovudine. Int. J. Pharm. 77 (1991) 71-74
119. Wintergerst U., Rolinski B., Bogner J.R., Notheis G., Goebel F.D., Roscher A.A., and Belohradsky B.H. Pharmacokinetics of zidovudine after rectal administration in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 41 (1997) 1143-1145
120. Seki T., Kawaguchi T., Juni K., Sugibayashi K., and Morimoto Y. Sustained transdermal delivery of zidovudine via controlled release of penetration enhancer. J. Control. Release 17 (1991) 41-47
121. Mukherji E., Millenbaugh N.J., and Au J.L.S. Percutaneous-absorption of 2′,3′-dideoxyinosine in rats. Pharm. Res. 11 (1994) 809-815
122. Kim D.D., and Chien Y.W. Transdermal delivery of dideoxynucleoside-type anti-HIV drugs. 1. Stability studies for hairless rat skin permeation. J. Pharm. Sci. 84 (1995) 1061-1066
123. Kim D.D., and Chien Y.W. Transdermal delivery of zalcitabine: in vitro skin permeation study. Aids 9 (1995) 1331-1336
124. Kim D.D., and Chien Y.W. Transdermal delivery of dideoxynucleoside-type anti-HIV drugs. 2. The effect of vehicle and enhancer on skin permeation. J. Pharm. Sci. 85 (1996) 214-219
125. Kim D.D., and Chien Y.W. Simultaneous skin permeation of dideoxynucleoside-type anti-HIV drugs. J. Control. Release 40 (1996) 67-76
126. Kim D.D., and Chien Y.W. Comparison of skin permeation of dideoxynucleoside-type anti-HIV drugs: alone virus combination. Drug Dev. Ind. Pharm. 22 (1996) 1047-1054
127. Kim D.D., Kim J.L., and Chien Y.W. Mutual hairless rat skin permeation-enhancing effect of ethanol/water system and oleic acid. J. Pharm. Sci. 85 (1996) 1191-1195
128. Thomas N.S., and Panchagnula R. Combination strategies to enhance transdermal permeation of zidovudine (AZT). Pharmazie 58 (2003) 895-898
129. Suwanpidokkul N., Thongnopnua P., and Umprayn K. Transdermal delivery of zidovudine (AZT): the effects of vehicles, enhancers, and polymer membranes on permeation across cadaver pig skin. AAPS PharmSciTech. 5 (2004) e48
130. Narishetty S.T., and Panchagnula R. Effect of l-menthol and 1,8-cineole on phase behavior and molecular organization of SC lipids and skin permeation of zidovudine. J. Control. Release 102 (2005) 59-70